Abstract:BACKGROUND: Vascular endothelial growth factor (VEGF) can specifically promote the division and proliferation of endothelial cells and the revascularization, finally induce angiopoiesis. Recently, VEGF-based gene therapy has been gradually used in clinical trials, but some limits on usually used vectors deserve further studies, including the low transfection efficiency of plasmid vector, the immunogenicity of adnovirus vector to host cells and the potential risk of infection. OBJECTIVE: To construct the non-pathogenic recombinant adeno-associated vires (AAV) co-expressing human vascular endethelial growth factor 165 (hVEGF165) and green fluorescent protein (GFP) label and measure the virus titer and assess its biological activity.DESIGN, TIME AND SETTING: The open experiment was performed at the Vitrus Laboratory of Shanxi Provincial Center for Disease Control and Prevention from March to September 2007.MATERIALS: AAV-293 virus packaging cell line, AAV HT-1080 cells were purchased from Swatagene, USA. E.coli DH5α was a stocked strain from Shanxi Provincial Center for Disease Control and Prevention. AAV Helper Free System (pAAV-IRES-GFP vector containing GFP label) was purchased from Stratagene, USA. Plasmid pUC18-hVEGF165 was constructed previously by Dr.Shi from Department of Orthopaedics of Second Affiliated Hospital of Xi'an Jiaotong University.METHODS: The hVEGF165 gone from plasmid pUC18-hVEGF165 was amplified and inserted into plasmid pAAV-IRES-hrGFP. Then recombinant plasmid pAAV-hVEGF165-IRES-hrGFP, pAAV-RC and pAAV-Helper were co-transfected into AAV-293 cells to complete rAAV-hVEGF165-IRES-hrGFP packaging through homologous recombination. The efficiency of A.AV packaging was monitored under a fluorescent microscope, and the recombinant viral particles were harvested from infected AAV-293 cells and further concentrated and purified. The recombinant virus infected the AAV-HT1080 cells, the virus titer was measured by fluorescence counting, and the recombinant AAV-hVEGF165-IRES-hrGFP was verified by the amplification of the exogenous gene of hVEGF165 from virus genome.MAIN OUTCOME MEASURES: Virus packaging efficiency was monitored under the fluorescence microscope. Virus filer was measured by fluorescent counting. The packaging of recombinant virus was determined by the amplification of the exogenous hVEGF165 gene.RESULTS: The amplified products were verified as hVEGF165 gene by DNA sequencing, and the recombinant pAAV-hVEGF165-IRES-hrGFP was confirmed by double digestion. The system provided a high packaging ratio of over 95% and the purified recombinant virus had a high titer of 5.5×1011 vp/mL. The recombinant virus was confirmed by exogenous human VEGF165 gene from virus genome.CONCLUSION: The non-pathogenic rAAV-hVEGF165-GFP simultaneously carrying hVEGF165 and GFP 1abel is successfully constructed, with a high titer and satisfying biological activity.

Construction and identification of retroviral vector expressing hypoxia-inducible factor-1α and EGFP fusions

Construction and identification of eukaryotic expression plasmid of recombinant human hypoxia-inducible factor-1α

Construction of Recombinant Eukaryotic Expression Vector Pegfpci-Hif-1α and Its Expression in Eukaryotic Cells PC12

Construction and identification of the recombinant retroviral vector to carry out hypoxia-regulated expression of neurotrophin-3

Construction of the Recombinant Adenovirus RNA Interference Vector of Human Hypoxia-Inducible Transcription Factor-1Α Gene and Its Effect on Expression of HIF-1α Gene in Human Lung Adenocarcinoma Cells SPCA-1

Construction and Identification of HIF-1αRNAi Lentiviral Vector

Construction and Identification of Mir RNAi Lentiviral Vector Targeting for HIF-1α

Construction and verification of a hypoxia-induced gene therapy vector targeting hepatocellular carcinoma

Gene Clone and Construction of Expression Vecter of Hypoxia Inducible Factor-1α in Rats

Establishment of A549 cell line with stable expression of HIF1α mediated by lentiviral vector

Construction and Target Gene Expression of Recombinant Adenovirus Vectors Containing Vascular Endothelial Growth Factor 165 and Angiopoietin-1

Cloning and Construction of Adenovirus Expressing Human Angiopoietin-1 or Vascular Endothelial Growth Factor

Construction of Recombinant HIF-1α and NIS Lentiviral Expression Plasmid and Its Functional Identification

Construction and Identification of Recombinant Adeno- Associated Virus Vector Co-Expressing Human Vascular Endothelial Growth Factor and Green Fluorescent Protein

Expression of Human Vascular Endothelial Growth Factor in Cultured NIH3T3 Cells

Establishment of Eukaryotic Expression System of Hlif Gene Via Retrovirus Vector

Construction of vector specifically expressed vascular endothelial growth factor gene in endothelial cells and research of its expressive character

Construction of Retroviral Vector Encoding Human Insulin-like Growth Factor-1 and Its Expression in Bone Marrow Stromal Cells

Construction of recombinant adenovirus vector containing a modified gene that codes for human hypoxia-inducible factor-1alpha without oxygen-dependent degradation domain.

Construction and identification of HIF-1α targeted RNAi lentiviral vector

Construction and functional identification of siRNA adenoviral vector targeting HIF-1α in mouse